Skip to main content

Table 3 Analyzing the Association Between Risankizumab Use and Achieving PASI 75 in Psoriasis Patients through Multiple Logistic Regression

From: Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia

Variable

Odds ratio (OR)

p-value

95% Confidence Interval (CI)

Risankizumab vs. Adalimumab

2.725

0.1628

0.667–11.140

Age

0.966

0.2243

0.913–1.021

Female vs. male

0.695

0.5558

0.207–2.332

Duration of illness

0.999

0.9888

0.927–1.077

Duration of treatment

1.265

0.3665

0.759–2.109

Number of comorbidities

1.308

0.3797

0.719–2.381

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us